Inpatient statin use and stroke recurrence in patients with or without diabetes mellitus

References

• Ergul A, Li W, Elgebaly MM, et al. Hyperglycemia, diabetes and stroke: focus on the cerebrovasculature. Vascul Pharmacol. 2009;51(1):44–49.
   PubMed Web of Science ®Google Scholar
• Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Internal Med. 2004;164(13):1422–1426.
   PubMedGoogle Scholar
• Hafez S, Coucha M, Bruno A, et al. Hyperglycemia, acute ischemic stroke, and thrombolytic therapy. Transl Stroke Res. 2014;5(4):442–453.
   PubMed Web of Science ®Google Scholar
• Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32(10):2426–2432.
   PubMed Web of Science ®Google Scholar
• Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004;109(21 Suppl 1):II42–8.
   PubMed Web of Science ®Google Scholar
• Bang CN, Okin PM. Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr Cardiol Rep. 2014;16(3):461.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their increased risk of inducing diabetes. Expert Opin Drug Saf. 2015;14(12):1835–1844.
   PubMed Web of Science ®Google Scholar
• Bernardi A, Rocha VZ, Faria-Neto JR. Use of statins and the incidence of type 2 diabetes mellitus. Revista da Associacao Medica Brasileira (1992). 2015;61(4):375–380.
   PubMed Web of Science ®Google Scholar
• Axsom K, Berger JS, Schwartzbard AZ. Statins and diabetes: the good, the bad, and the unknown. Curr Atheroscler Rep. 2013;15(2):299.
   PubMed Web of Science ®Google Scholar
• Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms? Curr Opin Lipidol. 2015;26(3):228–235.
   PubMed Web of Science ®Google Scholar
• Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–2539.
   PubMed Web of Science ®Google Scholar
• Korhonen MJ, Ruokoniemi P, Ilomaki J, et al. Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiol Drug Saf. 2016;25(2):161–169.
   PubMed Web of Science ®Google Scholar
• Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention By Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011;68(10):1245–1251.
   PubMedGoogle Scholar
• Wang Y, Cui L, Ji X, et al. The China national stroke registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke. 2011;6(4):355–361.
   PubMed Web of Science ®Google Scholar
• Aho K, Harmsen P, Hatano S, et al. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58(1):113–130.
   PubMed Web of Science ®Google Scholar
• Song B, Wang Y, Zhao X, et al. Association between statin use and short-term outcome based on severity of ischemic stroke: a cohort study. PloS One. 2014;9(1):e84389.
   PubMed Web of Science ®Google Scholar
• Jia Q, Zhao X, Wang C, et al. Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China national stroke registry. Stroke. 2011;42(10):2758–2762.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Sharma VK, et al. Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke. Neurology. 2016;86(12):1103–1111.
   PubMed Web of Science ®Google Scholar
• Flint AC, Conell C, Klingman JG, et al. Impact of increased early statin administration on ischemic stroke outcomes: A multicenter electronic medical record intervention. J Am Heart Assoc. 2016;5(8).
   PubMed Web of Science ®Google Scholar
• Hosomi N, Nagai Y, Kitagawa K, et al. Pravastatin reduces the risk of atherothrombotic stroke when administered within six months of an initial stroke event. J Atheroscler Thromb. 2018;25(3):262–268.
   PubMed Web of Science ®Google Scholar
• Song B, Wang Y, Zhao X, et al. Inpatient statin use is associated with decreased mortality of acute stroke patients with very low low-density lipoprotein cholesterol. J Stroke Cerebrovasc Dis. 2015;24(10):2369–2374.
   PubMed Web of Science ®Google Scholar
• Flint AC, Kamel H, Navi BB, et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology. 2012;78(21):1678–1683.
   PubMed Web of Science ®Google Scholar
• Kearney P, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125.
   PubMed Web of Science ®Google Scholar
• Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57(14):1535–1545.
   PubMed Web of Science ®Google Scholar
• Maki KC, Ridker PM, Brown WV, et al. The diabetes subpanel of the national lipid association expert P. An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S17–29.
   PubMed Web of Science ®Google Scholar
• Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol. 2004;15(3):269–278.
   PubMed Web of Science ®Google Scholar
• Fryirs M, Barter PJ, Rye KA. Cholesterol metabolism and pancreatic beta-cell function. Curr Opin Lipidol. 2009;20(3):159–164.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Ji R, Liu G, Shen H, et al. Persistence of secondary prevention medications after acute ischemic stroke or transient ischemic attack in Chinese population: data from China national stroke registry. Neurol Res. 2013;35(1):29–36.
   PubMed Web of Science ®Google Scholar
• Ding D, Lu CZ, Fu JH, et al. Association of antiplatelet therapy with lower risk of death and recurrent cerebrovascular events after ischemic stroke–results from the China ischemic stroke registry study. Circ J. 2009;73(12):2342–2347.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang CX, Wang YL, et al. Persistence with antihypertensive agents for 12 months after ischemic stroke reduces the rates of death and dependency. CNS Neurosci Ther. 2013;19(2):142–144.
   PubMed Web of Science ®Google Scholar